Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00513305 · ClinicalTrials.gov registry record · Phase 3
Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia
A Phase 3 study, sponsored by Cephalon.
- Terminated
- Registry status
- Phase 3
- Development phase
- 67
- Enrollment target
NCT00513305 is a Phase 3 study that was terminated before completion, run by Cephalon. The registered enrollment target is 67 participants.
The verdict
NCT00513305, a Phase 3 study, was terminated before completion, sponsored by Cephalon.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 67 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether low-dose cytarabine in combination with arsenic trioxide is more effective than low-dose cytarabine alone in achieving complete remission in elderly patients (≥60 years of age) with acute myeloid leukemia.
Interventions
- DRUG Arsenic trioxide
- DRUG Low-dose cytarabine alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00513305
The ClinicalTrials.gov registry entry for NCT00513305 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Arsenic trioxide is the first listed.
NCT00513305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00513305 about?
NCT00513305 is a clinical study titled "Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia". The primary objective of this study is to determine whether low-dose cytarabine in combination with arsenic trioxide is more effective than low-dose cytarabine alone in achieving complete remission in elderly patients (≥60 years of age) with acute myeloid leukemia.
What is the current status of trial NCT00513305?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 67 participants. The study started on 2007-10. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00513305?
The interventions under investigation include: Arsenic trioxide (DRUG), Low-dose cytarabine alone (DRUG).
Who is sponsoring clinical trial NCT00513305?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.